Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East

doi:10.12998/wjcc.v14.i9.118187

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

(31)

(43)

(0)

(12)

(618)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Mar 26, 2026; 14(9): 118187
Published online Mar 26, 2026. doi: 10.12998/wjcc.v14.i9.118187

Table 1 Baseline characteristics of the study population, n (%)/mean ± SD

Characteristic	Overall (n = 672)
Age at visit, year	54.2 ± 13.3
Gender
Males	474 (70.5)
Females	198 (29.5)
Ethnicity
Western Asia	240 (35.7)
Southern Asia	197 (29.3)
Northern Africa	115 (17.1)
South-Eastern Asia	63 (9.4)
Eastern Africa	16 (2.4)
Northern America	12 (1.8)
Others	29 (4.3)
First BMI result, kg/m²	26.2 ± 11.4
Last BMI result, kg/m²	26.2 ± 11.6
ICI therapy
Atezolizumab	84 (12.5)
Avelumab	4 (0.6)
Durvalumab	8 (1.2)
Ipilimumab	1 (0.2)
Nivolumab	162 (24.1)
Pembrolizumab	413 (61.5)

BMI: Body mass index; ICI: Immune checkpoint inhibitor.

Full Size Table

Citation: Chapra A, Ata F, Abdellatif A, Nofal M, Daniyal A, Mohammad Younus A, Shah JZ, Rasul K. Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East. World J Clin Cases 2026; 14(9): 118187
URL: https://www.wjgnet.com/2307-8960/full/v14/i9/118187.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i9.118187

Chapra A, Ata F, Abdellatif A, Nofal M, Daniyal A, Mohammad Younus A, Shah JZ, Rasul K. Incidence and clinical course of immune checkpoint inhibitor-related cardiac adverse events: A descriptive study from the Middle East. World J Clin Cases 2026; 14(9): 118187 [DOI: 10.12998/wjcc.v14.i9.118187]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.